The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing Thecnology in China

The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing Technology in China (IMPROVE-II ) -A Multicenter Cluster-Randomized Controlled Study

This study intends to construct the goal-oriented integrated intervention model through the intelligent bracelet automatic positioning and feedback system based spatiotemporal computing technology (FAST model) to promote the reconstruction of workflow in stroke centers and to shorten in-hospital delay of reperfusion treatment for AIS patients. This is a multicenter, cluster-randomized controlled study aims to verify the efficacy and safety of the FAST model.

This study intends to construct the goal-oriented integrated intervention model through the intelligent bracelet automatic positioning and feedback system based spatiotemporal computing technology (FAST model). Then a multicenter, cluster-randomized controlled study aims to verify the efficacy and safety of this FAST model.

This study will recruit 20 secondary or tertiary hospitals that meet the inclusion criteria, mainly distributed in the Beijing-Tianjin-Hebei-Shanxi-Neimenggu region. After 3 months of baseline information collection, 20 hospitals will be randomly assigned to the control and intervention groups. Then, the intervention group will install ithe intelligent bracelet automatic positioning and feedback system based spatiotemporal computing technology for 4 months. As the knowledge gained from the training may affect the identification of AIS patients, the duration of the training will keep as short as possible. We will conduct training to ensure that only trained caregivers and researchers master the use of the application to maintain the integrity of the intervention. During this 4-month period, both the control group and the intervention group will cease data collection. The FAST model intervention based on spatiotemporal computing technology will uniformly start after installation and training in each intervention group hospital. The intervention group will receive the goal-oriented integrated intervention model through the intelligent bracelet automatic positioning and feedback system based spatiotemporal computing technology for 8 months and collect information, mainly the critical time information of the AIS reperfusion therapy process. In the control group, only information will be collected.

We will compare the critical treatment time information, Door to Needle time and Door to Puncture time, etc., between the two groups and conduct a 3-month follow-up.

Inclusion Criteria:

Hospitals#

1. Secondary or tertiary public hospitals with an emergency department that receive patients with AIS.
2. Admit at least 50 patients of AIS within 4.5 hours after onset each month.
3. Have the capacity of intravenous thrombolytic therapy or/and endovascular treatment.
4. Voluntarily participate in this research and cooperate with the installation of bluetooth positioning device and the improvement of AIS emergency procedures.
5. Have good cooperation relationship among the department of Neurology, Emergency, Interventional department, Neurosurgery department, Laboratory department and Radiology department.
6. Have ability to establish or participate in the establishment of patient information database and arrange a person responsible for the collection of case information.

Patients# Patients who are ≥18 years old are eligible for inclusion if they present with AIS diagnosed by CT and/or MRI, arrive at hospital within 4.5 hours after symptom onset, sign the informed consent form and agree to follow up until 3 months after stroke onset.

Exclusion Criteria:

Hospitals#

1. Hospital that unable to cooperate and complete the research.
2. Hospitals that are participating in other AIS medical quality improvement projects or related clinical trials.

Patients#

1. Patients refuse to sign informed consent and follow up until 3 months after stroke onset.
2. Patients with mild nondisabling stroke (Defined as no measurable neurologic deficit, or NIHSS≤3 with only one of the following isolated symptoms: isolated facial paralysis; mild cortical blindness; mild hemianesthesia; mild hemiataxia.)
3. Life expectancy three-months or less by judgment of the investigator.
4. Participation in any interventional study that may affect the outcome